Displaying all 3 publications

Abstract:
Sort:
  1. Sen CJ, Cheng YC
    Afr J Paediatr Surg, 2024 Jul 01;21(3):204-206.
    PMID: 39162758 DOI: 10.4103/ajps.ajps_159_22
    A chemoport is widely used in paediatric oncology population. Removal is a relatively easy procedure, but difficulty can be encountered in case the catheter is densely adherent to the vascular wall. It is a rare complication and is associated with long indwelling duration and acute lymphoblastic leukaemia (ALL). Forceful traction can lead to vascular injury and high morbidity. Herein, we report a 7-year-old girl with precursor B ALL who had delayed chemoport removal due to the coronavirus disease (COVID-19) pandemic. The removal process was difficult, as the catheter was adherent to the right innominate vein. Out of panic, the surgeon pulled it out forcefully. Fortunately, the catheter and its fragment were successfully retrieved completely and the child was discharged the next day. The management strategy varies and ranges from minimally invasive to open surgery. Leaving a stuck chemoport catheter in situ can be a bailout method or part of conservative management.
  2. Chuah XF, Lee KT, Cheng YC, Lee PF, Lu SY
    ACS Omega, 2017 Aug 31;2(8):4261-4268.
    PMID: 30023720 DOI: 10.1021/acsomega.7b00698
    A superfast, room-temperature, one-step carrier-solvent-assisted interfacial reaction process was developed to prepare Ag/AgFeO2 composite nanocrystals (NCs) of less than 10 nm in size within a 1 min reaction time. These composite NCs were with a direct energy band gap of 2.0 eV and were paramagnetic, making them suitable for optical activation and magnetic manipulation. These composite NCs, applied as a photocatalyst for the treatment of HeLa cells, achieved a significant reduction of 74% in cell viability within 30 min. These Ag/AgFeO2 composite NCs proved to be a promising magnetically guidable photocatalyst for cancer cell treatment.
  3. Cheng YC, Stanne TM, Giese AK, Ho WK, Traylor M, Amouyel P, et al.
    Stroke, 2016 Feb;47(2):307-16.
    PMID: 26732560 DOI: 10.1161/STROKEAHA.115.011328
    BACKGROUND AND PURPOSE: Although a genetic contribution to ischemic stroke is well recognized, only a handful of stroke loci have been identified by large-scale genetic association studies to date. Hypothesizing that genetic effects might be stronger for early- versus late-onset stroke, we conducted a 2-stage meta-analysis of genome-wide association studies, focusing on stroke cases with an age of onset <60 years.

    METHODS: The discovery stage of our genome-wide association studies included 4505 cases and 21 968 controls of European, South-Asian, and African ancestry, drawn from 6 studies. In Stage 2, we selected the lead genetic variants at loci with association P<5×10(-6) and performed in silico association analyses in an independent sample of ≤1003 cases and 7745 controls.

    RESULTS: One stroke susceptibility locus at 10q25 reached genome-wide significance in the combined analysis of all samples from the discovery and follow-up stages (rs11196288; odds ratio =1.41; P=9.5×10(-9)). The associated locus is in an intergenic region between TCF7L2 and HABP2. In a further analysis in an independent sample, we found that 2 single nucleotide polymorphisms in high linkage disequilibrium with rs11196288 were significantly associated with total plasma factor VII-activating protease levels, a product of HABP2.

    CONCLUSIONS: HABP2, which encodes an extracellular serine protease involved in coagulation, fibrinolysis, and inflammatory pathways, may be a genetic susceptibility locus for early-onset stroke.

Related Terms
Filters
Contact Us

Please provide feedback to Administrator ([email protected])

External Links